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ABSTRACT 486 
To dissect the genetic architecture of blood pressure and assess effects on target-organ damage, 487 
we analyzed 128,272 SNPs from targeted and genome-wide arrays in 201,529 individuals of European 488 
ancestry and genotypes from an additional 140,886 individuals were used for validation. We identified 489 
66 blood pressure loci, of which 17 were novel and 15 harbored multiple distinct association signals.  490 
The 66 index SNPs were enriched for cis-regulatory elements, particularly in vascular endothelial cells, 491 
consistent with a primary role in blood pressure control through modulation of vascular tone across 492 
multiple tissues.  The 66 index SNPs combined in a risk score showed comparable effects in 64,421 493 
individuals of non-European descent.  The 66-SNP blood pressure risk score was significantly associated 494 
with target-organ damage in multiple tissues, with minor effects in the kidney. Our findings expand 495 
current knowledge of blood pressure pathways and highlight tissues beyond the classic renal system in 496 
blood pressure regulation.  497 
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INTRODUCTION 498 
There are considerable physiological, clinical and genetic data that point to the kidney as the 499 
major regulator of blood pressure (BP) and to renal damage as a consequence of long-term BP elevation.  500 
However, alternative hypotheses, such as increasing systemic vascular resistance, are also serious 501 
contenders to explain the rise of BP with increasing age, but with limited genetic support. The genetic 502 
basis of elevated blood pressure or hypertension (HTN) involves many loci that have been identified 503 
using large-scale analyses of candidate genes1,2, linkage studies, and genome-wide association studies 504 
(GWAS)3-12.  The genes underlying BP regulation can help resolve many of the open questions regarding 505 
BP (patho-) physiology.  While ~40-50% of BP variability is heritable13,14, the genetic variation identified 506 
to date explains only ~2%1-12. 507 
The Cardio-MetaboChip is a custom genotyping microarray designed to facilitate cost-effective 508 
follow-up of nominal associations for metabolic and cardiovascular traits, including BP.  This array 509 
comprises 196,725 variants, including ~5,000 SNPs with nominal (P <0.016) evidence of BP association in 510 
our previous GWAS meta-analysis5.  Furthermore, the array includes several dense scaffolds for fine 511 
mapping of selected loci spanning, on average, genomic regions of 350 kilobases5,16, of which 24 include 512 
genome-wide significant BP association in the current study5,16. 513 
RESULTS 514 
Novel genetic loci associated with systolic and diastolic BP 515 
 We performed meta-analyses of association summary statistics from a total of 201,529 516 
individuals of European (EUR) ancestry from 74 studies: (i) 109,096 individuals from 46 studies 517 
genotyped on Cardio-MetaboChip; and (ii) 92,433 individuals from 28 studies with imputed genotype 518 
data from genome-wide genotyping at variants included on the Cardio-MetaboChip. Twenty-four of the 519 
28 studies with genome-wide genotyping data had contributed to previous analyses (Supplementary 520 
Tables 1-3)5,7. 521 
BP was measured using standardized protocols in all studies5,17 (Supplementary Table 1, Online 522 
methods). Association statistics for systolic and diastolic BP (SBP and DBP) in models adjusting for age, 523 
age2, sex, and body mass index (BMI), were obtained for each study separately, with study-specific 524 
genomic control applied to correct for possible population structure.  Fixed-effects meta-analysis 525 
proceeded in 4 stages, separately for the following SNP associations: Stage 1, using results based on 46 526 
studies using Cardio-MetaboChip genotypes of 109,096 participants; Stage 2, using additional results 527 
based on imputed genotypes from genome-wide genotyping arrays in 4 previously unpublished studies; 528 
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Stage 3 using imputed genotypes from genome-wide genotyping arrays in 24 previously published 529 
studies5; and Stage 4,  the joint meta-analysis of Stages 1-3 including a total of 201,529 independent 530 
individuals (Supplementary Figure 1, Supplementary Tables 2-3, Supplementary Note). To account for 531 
population structure between studies in Stages 1-3 of our meta-analysis, genomic control correction was 532 
applied to meta-analysis results from each of these stages in an approach aggregating summary 533 
statistics from GWAS and Cardio-MetaboChip studies18,19. 534 
After stage 4, 67 loci attained genome-wide significance (P < 5 x 10-8), 18 of which were not 535 
previously reported in the literature (Supplementary Table 4). Quantile-quantile plots  of the stage 4 536 
meta-analysis showed an excess of small P values, with an elevated genomic control lambda estimate 537 
that was persistent, albeit attenuated, after excluding all 66 loci (Supplementary Figure 2).  This 538 
observation is compatible with either residual uncorrected population stratification or the presence of a 539 
large number of variants that are truly associated with BP but fail to achieve genome-wide significance 540 
in the current meta-analysis.  The Cardio-MetaboChip array’s inclusion of SNPs from a prior BP GWAS5 541 
does not appear to be the sole explanation, as we did not observe a significant decrease of the excess of 542 
small P values after exclusion of all SNPs that were included on the Cardio-MetaboChip based on 543 
nominal BP association (Supplementary Figures 3 and 4).  Since the quantile-quantile plots continued to 544 
show deviation from the null expectation, we sought additional validation for 18 variants attaining 545 
genome-wide significance, but without prior support in the literature, in up to 140,886 individuals of 546 
European ancestry from UK Biobank20.  For these SNPs, we performed a stage 5 meta-analysis combining 547 
the association summary statistics from stage 4 and UK Biobank, in a total of up to 342,415 individuals 548 
(Supplementary Table 5). 549 
Upon stage 5 meta-analysis, 17 of 18 variants retained genome-wide significance for the primary 550 
trait (SBP or DBP result with the lower P value).  The one variant that was not genome-wide significant 551 
had a borderline P value of 4.49 x 10-8 at stage 4.  These findings are consistent with appropriate 552 
calibration of the association test statistics at stage 4 such that observing one failure among 18 553 
validation tests is consistent with the use of a threshold (P < 5 x 10-8) designed to have a 1 in 20 chance 554 
of a result as or more extreme solely due to chance.  In total, 66 loci attained genome-wide significance: 555 
13 loci for SBP only, 12 loci for DBP only, and 41 loci for both traits. Of these, 17 BP loci were novel, 556 
while 49 were previously reported at genome-wide significance (Table 1 and Figure 1). 557 
Compared with previously reported BP variants5,7,21, the average absolute effect size of the 558 
newly discovered variants is smaller, with comparable minor allele frequency (MAF), presumably owing 559 
to the increased power of a larger sample size (Table 2).  As expected from the high correlation between 560 
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SBP and DBP effects, the observed directions of effects for the two traits were generally concordant 561 
(Supplementary Figure 5), and the absolute effect sizes were inversely correlated with MAF (Table 1 562 
and Supplementary Figure 6). The 66 BP SNPs explained 3.46% and 3.36% of SBP and DBP variance, 563 
respectively, a modest increase from 2.95% and 2.78% for SBP and DBP, respectively, for the 49 564 
previously reported SNPs (Supplementary Note). The low percent variance explained is consistent with 565 
estimates that large numbers of common variants with weak effects at a large number of loci influence 566 
BP5. 567 
Signal refinement at the 66 BP loci 568 
To identify distinct signals of association at the 66 BP loci and the variants most likely to be 569 
causal for each, we started with an approximate conditional analysis using a model selection procedure 570 
implemented in the GCTA-COJO package22,23 as well as a detailed literature review of all published BP 571 
association studies.  GCTA-COJO analysis was performed using the association summary statistics for SBP 572 
and DBP from the Stage 4 EUR ancestry meta-analyses, with the linkage disequilibrium (LD) between 573 
variants estimated on the basis of Cardio-MetaboChip genotype data from 7,006 individuals of EUR 574 
ancestry from the GoDARTS cohort24.  More than one distinct BP association signal was identified at 13 575 
loci at P < 5 x 10-8 (Supplementary Table 6, Supplementary Figures 7, and Supplementary Note).  At six 576 
loci, the distinct signals were identified for both SBP and DBP analyzed separately; these trait-specific 577 
associations were represented by the same or highly correlated (r2 > 0.8) SNPs at 5 of the 6 loci 578 
(Supplementary Tables 7 and 8).  We repeated GCTA-COJO analyses using the same summary 579 
association results, but with a different reference sample for LD estimates (WTCCC1-T2D/58BC, N = 580 
2,947, Supplementary Note) and observed minimal differences arising from minor fluctuations in the 581 
association P value in the joint regression models (Supplementary Tables 7 and 8).  LD-based 582 
comparisons of published association signals at established BP loci, and the current study’s findings 583 
suggested that at 10 loci, the signals identified by the single-SNP and the GCTA-COJO analyses were 584 
distinct from those reported in the literature (Supplementary Table 9). 585 
We then performed multivariable regression modeling in a single large cohort (Women’s 586 
Genome Health Study, WGHS, N = 23,047) with simultaneous adjustment for both 1) all combinations of 587 
putative index SNPs for each distinct signal from the GCTA-COJO conditional analyses, and 2) all index 588 
SNPs for all potential distinct signals identified by our literature review (Supplementary Table 9, 589 
Supplementary Note).  Although WGHS is very large as a single study, power is reduced in a single 590 
sample compared to that in the overall meta-analysis (23k vs. 342k individuals) and consequently the 591 
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failure to reach significance does not represent non-replication for individual SNPs.  The WGHS analysis 592 
supported two distinct association signals at eight of 13 loci identified in the GCTA-COJO analysis, but 593 
could not provide support for the remaining five (Supplementary Table 10).  The joint SNP modeling in 594 
WGHS additionally supported two distinct signals of association at three other loci (GUCY1A3-GUCY1B3, 595 
SYNPO2L and TBX5-TBX3), at which the SNP identified in the current study is distinct from that 596 
previously reported in the literature5,11. 597 
 We sought to refine the localization of likely functional variants at loci with high-density 598 
coverage on the Cardio-MetaboChip. We followed a Bayesian approach to define, for each signal, 599 
credible sets of variants that have 99% probability of containing or tagging the causal variant 600 
(Supplementary Note).  To improve the resolution of the method, the analyses were restricted to 24 601 
regions selected to fine map (FM) genetic associations, and that included at least one SNP reaching 602 
genome-wide significance in the current meta-analyses (Supplementary Table 11).  Twenty-one of the 603 
Cardio-MetaboChip FM regions were BP loci in the original design, with three of the newly discovered 604 
BP loci in FM regions that were originally selected for other non-BP traits.  We observed that the 99% 605 
credible SNP sets at five BP loci spanned <20kb.  The greatest refinement was observed at the SLC39A8 606 
locus for SBP and DBP, and at the ZC3HC1 and PLCE1 loci for DBP, where the 99% credible sets included 607 
only the index variants (Supplementary Table 12). Although SNPs in credible sets were primarily non-608 
coding, they included one synonymous and seven non-synonymous variants that attained high posterior 609 
probability of driving seven distinct association signals at six BP loci (Supplementary Table 12).  Of 610 
these, three variants alone account for more than 95% of the posterior probability of driving the 611 
association signal observed at each of three loci (Supplementary Table 12 and 13). Despite reduced 612 
statistical power, the analyses restricted to the samples with Cardio-MetaboChip genotypes only 613 
(N = 109,096) identified the majority of SNPs identified in the GWAS+Cardio-MetaboChip data 614 
(Supplementary Table 12). The full list of SNPs in the 99% credible sets are listed in Supplementary 615 
Table 13. 616 
What do the BP variants do? 617 
Index SNPs or their proxies (r2 > 0.8) altered amino acid sequence at 11 of 66 BP loci (Table 1).  618 
Thus, the majority of BP-association signals are likely driven by non-coding variants hypothesized to 619 
regulate expression of some nearby gene in cis.  To characterize their effects, we first sought SNPs 620 
associated with gene expression (eSNPs) from a range of available expression data which included 621 
hypertension target end organs and cells of the circulatory system (heart tissue, kidney tissue, brain 622 
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tissue, aortic endothelial cells, blood vessels) and other tissue/cell types (CD4+ macrophages, monocytes 623 
lymphoblastoid cell lines, skin tissue, fat tissue, and liver tissue).  Fourteen BP-associated SNPs at the 624 
MTHFR-NPPB, MDM4, ULK4, CYP1A1-ULK3, ADM, FURIN-FES, FIGN, and PSMD5 loci were eSNPs across 625 
different tissues (Supplementary Table 14).  Of these 14 eSNPs, three were also predicted to alter the 626 
amino acid sequence at the MTHFR-NPPB, MAP4 and ULK4 loci, providing two potential mechanisms to 627 
explore in functional studies.  Second, we used gene expression levels measured in whole blood in two 628 
different samples each including >5,000 individuals of EUR descent.  We tested whether the lead BP SNP 629 
was associated with expression of any transcript in cis (<1Mb from the lead SNP at each locus) at a false 630 
discovery rate (FDR) of < 0.05, accounting for all possible cis-transcript association tests genome-wide.  631 
It is likely that we did not genotype the causal genetic variant underlying each BP association signal; a 632 
nearby SNP-transcript association, due to LD, may therefore reflect an independent genetic effect on 633 
expression that is unrelated to the BP effect.  Consequently, we assumed that the lead BP SNP and the 634 
most significant eSNP for a given transcript should be highly correlated (r2 > 0.7).  Furthermore, we 635 
assumed that the significance of the transcript association with the lead BP SNP should be substantially 636 
reduced in a conditional model adjusting for the best eSNP for a given transcript.  Eighteen SNPs at 15 637 
loci were associated with 22 different transcripts, with a total of 23 independent SNP-transcript 638 
associations (three SNPs were associated with two transcripts each, Supplementary Table 15, 639 
Supplementary Note).  The genes expressed in a BP SNP allele-specific manner are clearly high-priority 640 
candidates to mediate the BP association.  In whole blood, these genes included obvious biological 641 
candidates such as GUCY1A3, encoding the alpha subunit of the soluble guanylate cyclase protein, and 642 
ADM, encoding adrenomedullin, both of which are known to induce vasodilation25,26. There was some 643 
overlap of eSNPs between the whole blood and other tissue datasets at the MTHFR-NPPB, MDM4, 644 
PSMD5, ULK4 and CYP1A1-ULK3 loci, illustrating additional potentially causal genes for further study. 645 
An alternative method for understanding the effect on BP of non-coding variants is to determine 646 
whether they fall within DNaseI hypersensitivity sites (DHSs). We performed two analyses to investigate 647 
whether BP SNPs or their LD proxies (r2 > 0.8) were enriched in DHSs in a cell-type-specific manner 648 
(Supplementary Note).  First, we used Epigenomics Roadmap and ENCODE DHS data from 123 adult cell 649 
lines or tissues27-29 to estimate the fold increase in the proportion of BP SNPs mapping to DHSs 650 
compared to SNPs associated at genome-wide significance with non-BP phenotypes from the NHGRI 651 
GWAS catalog30.  We observed that 7 out of the 10 cell types with the greatest relative enrichment of BP 652 
SNPs mapping to DHSs were from blood vessels (vascular or micro-vascular endothelial cell-lines or cells) 653 
and 11 of the 12 endothelial cells were among the top quarter most enriched among the 123 cell types 654 
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(Figure 2 and Supplementary Table 16).  In a second analysis of an expanded set of tissues and cell lines, 655 
in which cell types were grouped into tissues (Supplementary Table 17), BP-associated SNP enrichment 656 
in DHSs in blood vessels was again observed (P = 1.2 x 10-9), as well as in heart samples (P = 5.3 x 10-8; 657 
Supplementary Table 18). 658 
We next tested whether there was enrichment of BP SNPs in H3K4me331 sites, a methylation 659 
mark associated with both promoter and enhancer DNA. We observed significant enrichment in a range 660 
of cell types including CD34 primary cells, adult kidney cells, and muscle satellite cultured cells 661 
(Supplementary Table 19).  Enrichment of BP SNPs in predicted strong and weak enhancer states and in 662 
active promoters32 in a range of cell types was also observed (Supplementary Table 20, Supplementary 663 
Figure 8). 664 
We used Meta-Analysis Gene-set Enrichment of variaNT Associations (MAGENTA)33 to attempt 665 
to identify pathways over-represented in the BP association results.  No gene sets meeting experiment-666 
wide significance for enrichment for BP association were identified by MAGENTA after correction for 667 
multiple testing, although some attained nominal significance (Supplementary Table 21, Supplementary 668 
Note).  We also adapted the DEPICT34 pathway analysis tool (Data-driven Expression Prioritized 669 
Integration for Complex Traits) to identify assembled gene-sets that are enriched for genes near 670 
associated variants, and to assess whether genes from associated loci were highly expressed in 671 
particular tissues or cell types.  Using the extended BP locus list based on genome-wide significant loci 672 
from this analysis and previously published SNPs that may not have reached genome-wide significance 673 
in the current analysis (Supplementary Table 9), we identified five significant (FDR ≤ 5%) gene sets: 674 
abnormal cardiovascular system physiology, G Alpha 1213 signaling events, embryonic growth 675 
retardation, prolonged QT interval, and abnormal vitelline vasculature morphology.  We also found that 676 
suggestive SBP and DBP associations (P < 1 x 10-5) were enriched for reconstituted gene-sets at DBP loci 677 
(mainly related to developmental pathways), but not at SBP loci (Supplementary Table 22, 678 
Supplementary Note).  In a final analysis, we assessed Cardio-MetaboChip SNPs at the fine-mapping loci 679 
using formaldehyde-assisted isolation of regulatory elements (FAIRE-gen) in lymphoblastoid cell lines35.  680 
Our results provided support for two SNPs, one of which SNP (rs7961796 at the TBX5-TBX3 locus) was 681 
located in a regulatory site.  Although the other SNP (rs3184504 at the SH2B3 locus) is a non-682 
synonymous variant, there was also a regulatory site indicated by DNaseI and H3K4me1 signatures at 683 
the locus, making the SNP a potential regulatory variant (Supplementary Table 23)36.  Both SNPs were 684 
included in the list of 99% credible SNPs at each locus. 685 
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Asian- and African ancestry BP SNP association 686 
We tested the 66 lead SNPs at the established and novel loci for association with BP in up to 687 
20,875 individuals of South Asian (SAS) ancestry (PROMIS and RACE studies), 9,637 individuals of East 688 
Asian (EAS) ancestry (HEXA, HALST, CLHNS, DRAGON, and TUDR studies), and 33,909 individuals of 689 
African (AFR) ancestry (COGENT-BP consortium, Jupiter, SPT, Seychelles, GXE, and TANDEM studies).  As 690 
expected, the effect allele frequencies are very similar across studies of the same ethnicity, but 691 
markedly different across different ancestry groups (Supplementary Figure 9).  Many associations of 692 
individual SNPs failed to reach P < 0.05 for the BP trait with the lower P value (Supplementary Table 24), 693 
which could potentially be due to the much lower statistical power at the sample sizes available, 694 
different patterns of LD at each locus across ancestries, variability in allele frequency, or true lack of 695 
association in individuals of a given non-European ancestry.  The low statistical power for the great 696 
majority of SNPs tested is visible considering SNP-by-SNP power calculations using European ancestry 697 
effect sizes (Supplementary Table 24).  However, concordant directions of allelic effects for both SBP 698 
and DBP were observed for 45/66 SNPs in SAS, 36/60 SNPs in EAS, and 42/66 SNPs in AFR samples: the 699 
strongest concordance with SAS may not be surprising because South Asians are more closely related to 700 
Europeans than are East Asians or Africans.  Moreover, strong correlation of effect sizes was observed 701 
between EUR samples with SAS, EAS, or AFR samples (r = 0.55, 0.60, and 0.48, respectively). A 66-SNP 702 
SBP or DBP risk score were significant predictors of SBP and DBP in all samples. A 1 mm Hg higher SBP or 703 
DBP risk score in EUR samples was associated with a 0.58/0.50 mm Hg higher SBP/DBP in SAS samples 704 
(SBP P = 1.5 x 10-19, DBP P = 3.2 x 10-15), 0.49/0.50 mm Hg higher SBP/DBP in EAS samples (SBP 705 
P = 1.9 x 10-10, DBP P = 1.3 x 10-7), and 0.51/0.47 mm Hg higher SBP/DBP in AFR samples (SBP 706 
P = 2.2 x 10-21, DBP P = 6.5 x 10-19).  The attenuation of the genetic risk score estimates in non-European 707 
ancestries is presumably due to inclusion of a subset of variants that lack association in the non-708 
European or admixed samples. 709 
We subsequently performed a trans-ethnic meta-analysis of the 66 SNPs in all 64,421 samples 710 
across the three non-European ancestries.  After correcting for 66 tests, 12/66 SNPs were significantly 711 
associated with either SBP or DBP (P < 7.6 x 10-4), with a correlation of EUR and non-EUR effect 712 
estimates of 0.77 for SBP and 0.67 for DBP; the European-ancestry SBP or DBP risk score was associated 713 
with 0.53/0.48 mm Hg higher BP per predicted mm Hg SBP/DBP respectively (SBP P < 6.6 x 10-48, DBP 714 
P < 1.3 x 10-38).  For 7 of the 12 significant SNPs, no association has previously been reported in genome-715 
wide studies of non-European ancestry.  Some heterogeneity of effects was observed between 716 
European and non-European effect estimates (Supplementary Table 24).  Taken together, these findings 717 
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suggest that, in aggregate, BP loci identified using data from individuals of EUR ancestry are also 718 
predictive of BP in non-EUR samples, but larger non-European sample sizes will be needed to establish 719 
precisely which individual SNPs are associated in a given ethnic group. 720 
Impact on hypertensive target organ damage 721 
Long-term elevated BP causes target organ damage, especially in the heart, kidney, brain, large 722 
blood vessels, and the retinal vessels37.  Consequently, the genetic effect of the 66 SBP and DBP SNPs on 723 
end-organ outcomes can be directly tested using the risk score, although some outcomes lacked results 724 
for a small number of SNPs.  Interestingly, BP risk scores significantly predicted (Supplementary Note) 725 
coronary artery disease risk, left ventricular mass and wall thickness, stroke, urinary albumin/creatinine 726 
ratio, carotid intima-medial thickness and central retinal artery caliber, but not heart failure or other 727 
kidney phenotypes, after accounting for the number of outcomes examined (Table 3). Because outlier 728 
effects can affect risk scores, we repeated the risk score analysis removing iteratively SNPs that 729 
contributed to statistical heterogeneity (SNP-trait effects relative to SNP-BP effects). Heterogeneity was 730 
defined based on a multiple testing adjusted significance threshold for Cochran’s Q test of homogeneity 731 
of effects (Supplementary Note).  The risk score analyses restricted to the subset of SNPs showing no 732 
heterogeneity of effect revealed essentially identical results, with the exception that urinary 733 
albumin/creatinine ratio was no longer significant.  The per-SNP results are provided in Supplementary 734 
Table 25 and Supplementary Figures 10.  Because large-scale GWAS of non-BP cardiovascular risk 735 
factors are available, we examined the BP risk scores as predictors of other cardiovascular risk factors: 736 
LDL-cholesterol, HDL-cholesterol, triglycerides, type 2 diabetes, BMI, and height. We observed nominal 737 
(P <0.05) associations of the BP risk scores with risk factors, although mostly in the opposite direction to 738 
the risk factor-CVD association (Supplementary Table 26).  The failure to demonstrate an effect of BP 739 
risk scores on heart failure may reflect limited power from a modest sample size, but the lack of 740 
significant effects on renal measures suggests that the epidemiologic relationship of higher BP and 741 
worse renal function may not reflect direct consequences of BP elevation. 742 
DISCUSSION 743 
The study reported here is the largest to date to investigate the genomics of BP in multiple 744 
continental ancestries.  Our results highlight four major features of inter-individual variation in BP: (1) 745 
we identified 66 (17 novel) genome-wide significant loci for SBP and DBP by targeted genotyping in up 746 
to 342,415 individuals of European ancestry that cumulatively explain ~3.5% of the trait; (2) the variants 747 
were enriched for cis-regulatory elements, particularly in vascular endothelial cells; (3) the variants had 748 
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broadly comparable BP effects in South Asians, East Asian and Africans, albeit in smaller sample sizes; 749 
and, (4) a 66 SNP risk-score predicted target organ damage in the heart, cerebral vessels, carotid artery 750 
and the eye with little evidence for an effect in kidneys.  Overall, there was no enrichment of a single 751 
genetic pathway in our data; rather, our results are consistent with the effects of BP arising from 752 
multiple tissues and organs. 753 
Genetic and molecular analyses of Mendelian syndromes of hypertension and hypotension point 754 
largely to a renal origin, involving multiple rare deleterious mutations in proteins that regulate salt-755 
water balance38. This is strong support for Guyton’s hypothesis that the regulation of sodium excretion 756 
by the kidney and its effects on extracellular volume are a prime pathway determining intra-arterial 757 
pressure39.  However, our genetic data from unselected individuals in the general community argues 758 
against a single dominant renal effect. The 66 SNPs we identified are not chance effects, but have a 759 
global distribution and impact on BP that are consistent as measured by their effects across the many 760 
studies meta-analyzed.  That they are polymorphic across all continental ancestries argues for their 761 
origin and functional effects prior to human continental differentiation. 762 
However several of the 17 novel loci contain strong positional biological candidates, these are 763 
described in greater detail in Supplementary Table 27 and the Supplementary Note. The single most 764 
common feature we identified was the enrichment of regulatory elements for gene expression in 765 
vascular endothelial cells.  The broad distribution of these cells across both large and small vessels and 766 
across all tissues and organs suggest that functional variation in these cells affects endothelial 767 
permeability or vascular smooth muscle cell contractility via multiple pathways. These hypotheses will 768 
need to be rigorously tested in appropriate models, to assess the contribution of these pathways to BP 769 
control, and these pathways could also be targets for systemic anti-hypertensive therapy as they are for 770 
the pulmonary circulation42. 771 
In summary, these genetic observations may contribute to an improved understanding of BP 772 
biology and a re-evaluation of the pathways considered relevant for therapeutic BP control.773 
 24
SUPPLEMENTARY NOTE 774 
Supplementary Note is available in the online version of the paper. 775 
SUMMARY STATISTICS 776 
Full summary statistics (P values) are in the online version of the paper (file “ICBPCMfinalMeta.csv.zip”). 777 
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FIGURE LEGENDS 1053 
Figure 1. Manhattan plots for SBP and DBP from the stage 4 Cardio-MetaboChip-wide meta-analysis. 1054 
P values (expressed as -log10P) are plotted by physical genomic position labeled by chromosome. SNPs in 1055 
new loci (3.5MB window around the index SNP), identified in this study, are labeled in dark red (SBP) or 1056 
dark blue (DBP); SNPs in previously known loci are labeled in orange (SBP) or light blue (DBP).  The locus 1057 
names are indicated. The grey crosses indicate genomic positions at which the y-axis was truncated 1058 
(SNPs with P < 10-15). 1059 
Figure 2. Enrichment of DNAse hypersensitive sites among BP loci in different cell-types. Enrichment 1060 
analyses of SBP or DBP associated loci according to discovery P value using narrow peaks (panel A) or 1061 
broad peaks (panel B). SNPs were selected according to different P value cutoffs (x-axis) and a fold 1062 
enrichment of overlap with DNAse hypersensitive sites compared to unrelated GWAS SNPs was 1063 
calculated (y-axis) (see Supplementary Note). The 12 endothelial cell-lines are indicated in color and for 1064 
each endothelial cell-type the rank using the 10-14 P value cutoff is indicated. EC denotes endothelial 1065 
cells. 1066 
TABLE LEGENDS 1067 
Table 1.  SBP and DBP association at 66 loci. 1068 
Meta-analysis results of up to 342,415 individuals of European ancestry for SBP and DBP: Established 1069 
and new loci are grouped separately.  Nearest genes are shown as locus labels but this should not be 1070 
interpreted as support that the causal gene is the nearest gene.  The lead SNP with the lowest P value 1071 
for either BP trait is shown as the lead SNP and both SBP and DBP results are presented even if both are 1072 
not genome-wide significant.  The SNP effects are shown according to the effect in mm Hg per copy of 1073 
the coded allele (that is the allele coded 0, 1, 2) under an additive genetic model. “*” in the lead SNP 1074 
column indicates a non-synonymous coding SNP (either the SNP itself or another SNP in r2 >0.8). # 1075 
Established loci have smaller total sample sizes relative to novel loci (see Supplementary Note). 1076 
Table 2.  Overview of novel and known BP variant properties. 1077 
Key characteristics of the novel and established BP loci are shown. MAF and effect size estimates are 1078 
derived from the Cardio-MetaboChip data.  Variance explained estimates are estimated from one large 1079 
study (Supplementary Note). Novel loci are classified as previously unknown to be linked to BP by a 1080 
systematic PubMed review of all genes in a 200kb window (Supplementary Note). 1081 
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Table 3.  Prediction of hypertensive target organ damage by a multi-BP SNP score. 1083 
Shown are the estimated effects of a BP risk score comprised of up to 66 SNPs (see column “Total 1084 
#SNPs”) on risk of dichotomous outcome (as odds ratios) or increment in continuous measures per 1085 
predicted mmHg of the SBP or DBP score.  The effect sizes are expressed as incremental change in the 1086 
phenotype for quantitative traits and natural logarithm of the odds ratio for binary traits, per 1 mmHg 1087 
predicted increase in SBP or DBP. P values are bolded if they meet an analysis-wide significance 1088 
threshold (< 0.05/18 = 0.0028). Results for all SNPs (“all”) and for pruned results (“p”) are shown.  The 1089 
pruned results were obtained by iterative removal of SNPs from the risk score starting with the SNP with 1090 
lowest heterogeneity P value. Iterations to remove SNPs were continued until the heterogeneity P value 1091 
was < 0.0028 (see Supplementary Note).  The number of SNPs removed when calculating the pruned 1092 
results is indicated by “# SNPs rem.”.  The results per individual SNP can be found in Supplementary 1093 
Table 15.  CAD: coronary artery disease, LV: left ventricle, CKD: chronic kidney disease, eGFR: estimated 1094 
glomerular filtration rate, cr: creatinine, cIMT: carotid intima: media thickness. Var. type denotes the 1095 
variable type and cont. for continuous, or dic. for dichotomous. Eth. = Ethnicity, Consort. = Consortium, 1096 
EUR = European ancestry, EAS = East Asian ancestry. 1097 
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Table 1.  New and known BP loci. 1099 
Locus no. Locus name Lead SNP Chr Position 
(hg19) 
CA 
/NC 
Coded 
allele 
freq 
Traits SBP     DBP 
Effect SE P value Total N   Effect SE P value Total N# 
NEW 1 HIVEP3 rs7515635 1 42,408,070 T/C 0.468 SBP 0.307 0.0444 4.81E-12 340,969   0.1365 0.0263 2.05E-07 340,934 
NEW 2 PNPT1 rs1975487 2 55,809,054 A/G 0.464 DBP -0.2107 0.045 2.81E-06 337,522  -0.1602 0.0266 1.75E-09 337,517 
NEW 3 FGD5 rs11128722 3 14,958,126 A/G 0.563 SBP & DBP -0.3103 0.0469 3.61E-11 310,430   -0.1732 0.0279 5.16E-10 310,429 
NEW 4 ADAMTS9 rs918466 3 64,710,253 A/G 0.406 DBP -0.0865 0.0459 5.94E-02 336,671  -0.1819 0.027 1.73E-11 336,653 
NEW 5 TBC1D1-FLJ13197 rs2291435 4 38,387,395 T/C 0.524 SBP & DBP -0.3441 0.0449 1.90E-14 331,382   -0.156 0.0266 4.26E-09 331,389 
NEW 6 TRIM36 rs10077885 5 114,390,121 A/C 0.501 SBP & DBP -0.284 0.0444 1.64E-10 338,328  -0.1735 0.0263 3.99E-11 338,323 
NEW 7 CSNK1G3 rs6891344 5 123,136,656 A/G 0.819 DBP 0.2811 0.058 1.24E-06 338,688   0.2311 0.0343 1.58E-11 338,678 
NEW 8 CHST12-LFNG rs2969070 7 2,512,545 A/G 0.639 SBP & DBP -0.2975 0.0464 1.44E-10 335,991  -0.1821 0.0274 2.92E-11 335,972 
NEW 9 ZC3HC1 rs11556924 7 129,663,496 T/C 0.384 SBP & DBP -0.2705 0.0468 7.64E-09 325,929   -0.2141 0.0276 8.15E-15 325,963 
NEW 10 PSMD5 rs10760117 9 123,586,737 T/G 0.415 SBP 0.283 0.0457 6.10E-10 333,377  0.0999 0.0269 2.08E-04 333,377 
NEW 11 DBH rs6271* 9 136,522,274 T/C 0.072 SBP & DBP -0.5911 0.0899 4.89E-11 306,394   -0.4646 0.0532 2.42E-18 306,463 
NEW 12 RAPSN, PSMC3, SLC39A13 rs7103648 11 47,461,783 A/G 0.614 SBP & DBP -0.3349 0.0462 4.43E-13 335,614  -0.2409 0.0272 9.03E-19 335,592 
NEW 13 LRRC10B rs751984 11 61,278,246 T/C 0.879 SBP & DBP 0.4074 0.0691 3.80E-09 334,583   0.3755 0.0409 4.20E-20 334,586 
NEW 14 SETBP1 rs12958173 18 42,141,977 A/C 0.306 SBP & DBP 0.3614 0.0489 1.43E-13 331,007  0.1789 0.0289 5.87E-10 331,010 
NEW 15 INSR rs4247374 19 7,252,756 T/C 0.143 SBP & DBP -0.5933 0.0673 1.23E-18 302,458   -0.3852 0.0396 2.08E-22 302,459 
NEW 16 ELAVL3 rs17638167 19 11,584,818 T/C 0.047 DBP -0.4784 0.1066 7.13E-06 333,137  -0.3479 0.0632 3.71E-08 333,107 
NEW 17 CRYAA-SIK1 rs12627651 21 44,760,603 A/G 0.288 SBP & DBP 0.3905 0.0513 2.69E-14 310,738   0.2037 0.0301 1.36E-11 310,722 
EST 1 CASZ1 rs880315 1 10,796,866 T/C 0.641 SBP & DBP -0.475 0.062 2.09E-14 184,226  -0.257 0.038 1.34E-11 184,212 
EST 2 MTHFR-NPPB rs17037390 1 11,860,843 A/G 0.155 SBP & DBP -0.908 0.081 5.95E-29 195,493   -0.499 0.05 1.20E-23 195,481 
EST 3 ST7L-CAPZA1-MOV10 rs1620668 1 113,023,980 A/G 0.822 SBP & DBP -0.535 0.076 1.45E-12 197,966  -0.285 0.047 9.00E-10 197,948 
EST 4 MDM4 rs4245739 1 204,518,842 A/C 0.737 DBP 0.326 0.068 1.37E-06 191,594   0.243 0.041 4.63E-09 191,578 
EST 5 AGT rs2493134* 1 230,849,359 T/C 0.579 SBP & DBP -0.413 0.058 9.65E-13 199,505  -0.275 0.036 9.53E-15 199,502 
EST 6 KCNK3 rs2586886 2 26,932,031 T/C 0.599 SBP & DBP -0.404 0.059 5.94E-12 197,269   -0.254 0.036 1.92E-12 197,272 
EST 7 NCAPH rs772178 2 96,963,684 A/G 0.64 DBP -0.072 0.061 2.39E-01 192,513  -0.208 0.038 3.58E-08 192,501 
EST 8 FIGN-GRB14 rs1371182 2 165,099,215 T/C 0.443 SBP & DBP -0.444 0.058 1.89E-14 196,262   -0.252 0.036 1.50E-12 196,240 
EST 9 HRH1-ATG7 rs2594992 3 11,360,997 A/C 0.607 SBP -0.334 0.06 2.31E-08 189,895  -0.136 0.037 2.20E-04 189,854 
EST 10 SLC4A7 rs711737 3 27,543,655 A/C 0.604 SBP 0.334 0.058 9.93E-09 200,282   0.17 0.036 2.24E-06 200,260 
EST 11 ULK4 rs2272007* 3 41,996,136 T/C 0.18 DBP -0.11 0.077 1.52E-01 193,915  0.328 0.047 3.94E-12 193,900 
EST 12 MAP4 rs6442101* 3 48,130,893 T/C 0.692 SBP & DBP 0.396 0.062 1.62E-10 200,543   0.303 0.038 1.60E-15 200,534 
EST 13 MECOM rs6779380 3 169,111,915 T/C 0.539 SBP & DBP -0.439 0.06 1.85E-13 186,535  -0.239 0.037 6.87E-11 186,521 
EST 14 FGF5 rs1458038 4 81,164,723 T/C 0.3 SBP & DBP 0.659 0.065 5.36E-24 188,136   0.392 0.04 7.36E-23 188,088 
EST 15 ARHGAP24 rs17010957 4 86,719,165 T/C 0.857 SBP -0.498 0.082 1.51E-09 196,325  -0.173 0.051 6.63E-04 196,292 
EST 16 SLC39A8 rs13107325 4 103,188,709 T/C 0.07 SBP & DBP -0.837 0.127 4.69E-11 175,292   -0.602 0.078 1.63E-14 175,372 
EST 17 GUCY1A3-GUCY1B3 rs4691707 4 156,441,314 A/G 0.652 SBP -0.349 0.06 7.10E-09 198,246  -0.163 0.037 1.08E-05 198,226 
EST 18 NPR3-C5orf23 rs12656497 5 32,831,939 T/C 0.403 SBP & DBP -0.487 0.06 3.85E-16 194,831   -0.228 0.037 4.73E-10 194,829 
EST 19 EBF1 rs11953630 5 157,845,402 T/C 0.366 SBP & DBP -0.38 0.065 3.91E-09 167,698  -0.23 0.04 8.07E-09 167,708 
EST 20 HFE rs1799945* 6 26,091,179 C/G 0.857 SBP & DBP -0.598 0.086 3.28E-12 185,306   -0.43 0.053 3.10E-16 185,273 
EST 21 BAT2-BAT5 rs2187668 6 32,605,884 T/C 0.126 DBP -0.291 0.092 1.60E-03 189,806  -0.372 0.057 4.31E-11 189,810 
EST 22 ZNF318-ABCC10 rs6919440 6 43,352,898 A/G 0.57 SBP -0.337 0.058 4.92E-09 200,733   -0.125 0.035 4.25E-04 200,730 
EST 23 RSPO3 rs1361831 6 127,181,089 T/C 0.541 SBP & DBP -0.482 0.058 7.38E-17 197,027  -0.271 0.036 2.34E-14 197,012 
EST 24 PLEKHG1 rs17080093 6 150,997,440 T/C 0.075 DBP -0.564 0.111 3.83E-07 194,728   -0.411 0.068 1.71E-09 194,734 
EST 25 HOTTIP-EVX rs3735533 7 27,245,893 T/C 0.081 SBP & DBP -0.798 0.106 6.48E-14 197,881  -0.445 0.065 1.09E-11 197,880 
EST 26 PIK3CG rs12705390 7 106,410,777 A/G 0.227 SBP 0.619 0.069 2.69E-19 198,297   0.059 0.042 1.63E-01 198,290 
EST 27 BLK-GATA4 rs2898290 8 11,433,909 T/C 0.491 SBP 0.377 0.058 8.85E-11 197,759  0.167 0.036 3.17E-06 197,726 
EST 28 CACNB2 rs12243859 10 18,740,632 T/C 0.326 SBP & DBP -0.402 0.061 6.13E-11 199,136   -0.335 0.038 8.11E-19 199,124 
EST 29 C10orf107 rs7076398 10 63,533,663 A/T 0.188 SBP & DBP -0.563 0.076 1.72E-13 187,013  -0.409 0.047 2.55E-18 187,024 
EST 30 SYNPO2L rs12247028 10 75,410,052 A/G 0.611 SBP -0.364 0.063 8.16E-09 180,194   -0.159 0.039 3.89E-05 180,094 
EST 31 PLCE1 rs932764* 10 95,895,940 A/G 0.554 SBP & DBP -0.495 0.059 6.88E-17 195,577  -0.224 0.036 6.28E-10 195,547 
EST 32 CYP17A1-NT5C2 rs943037 10 104,835,919 T/C 0.087 SBP & DBP -1.133 0.105 2.35E-27 193,818   -0.482 0.064 4.48E-14 193,799 
EST 33 ADRB1 rs740746 10 115,792,787 A/G 0.73 SBP & DBP 0.486 0.067 4.59E-13 184,835  0.32 0.041 8.63E-15 184,868 
EST 34 LSP1-TNNT3 rs592373 11 1,890,990 A/G 0.64 SBP & DBP 0.484 0.063 2.02E-14 177,149   0.282 0.039 3.61E-13 177,134 
EST 35 ADM rs1450271 11 10,356,115 T/C 0.468 SBP & DBP 0.413 0.059 3.40E-12 191,246  0.199 0.036 4.11E-08 191,221 
EST 36 PLEKHA7 rs1156725 11 16,307,700 T/C 0.804 SBP & DBP -0.447 0.072 5.65E-10 200,889   -0.292 0.044 3.67E-11 200,899 
EST 37 SIPA1 rs3741378* 11 65,408,937 T/C 0.137 SBP -0.486 0.084 8.04E-09 194,563  -0.183 0.052 4.17E-04 194,551 
EST 38 FLJ32810-TMEM133 rs633185 11 100,593,538 C/G 0.715 SBP & DBP 0.522 0.067 6.97E-15 183,845   0.288 0.041 2.38E-12 183,825 
EST 39 PDE3A rs3752728 12 20,192,972 A/G 0.737 DBP 0.331 0.066 4.32E-07 200,440   0.319 0.04 2.35E-15 200,408 
EST 40 ATP2B1 rs11105354 12 90,026,523 A/G 0.84 SBP & DBP 0.909 0.081 3.88E-29 195,206  0.459 0.05 2.61E-20 195,195 
EST 41 SH2B3 rs3184504* 12 111,884,608 T/C 0.475 SBP & DBP 0.498 0.062 9.97E-16 177,067   0.362 0.038 1.28E-21 177,122 
EST 42 TBX5-TBX3 rs2891546 12 115,552,499 A/G 0.11 DBP -0.529 0.1 1.36E-07 172,012  -0.38 0.061 4.71E-10 171,980 
EST 43 CYP1A1-ULK3 rs936226 15 75,069,282 T/C 0.722 SBP & DBP -0.549 0.067 3.06E-16 187,238   -0.363 0.041 1.03E-18 187,221 
EST 44 FURIN-FES rs2521501 15 91,437,388 A/T 0.684 SBP & DBP -0.639 0.069 3.35E-20 164,272  -0.358 0.042 1.85E-17 164,255 
EST 45 PLCD3 rs7213273 17 43,155,914 A/G 0.658 SBP -0.413 0.066 4.71E-10 164,795   -0.185 0.041 7.23E-06 164,788 
EST 46 GOSR2 rs17608766 17 45,013,271 T/C 0.854 SBP -0.658 0.083 2.27E-15 188,895  -0.218 0.051 1.95E-05 188,928 
EST 47 ZNF652 rs12940887 17 47,402,807 T/C 0.38 DBP 0.321 0.06 7.06E-08 192,546   0.261 0.037 1.07E-12 192,524 
EST 48 JAG1 rs1327235 20 10,969,030 A/G 0.542 SBP & DBP -0.395 0.059 2.23E-11 192,680  -0.308 0.036 1.78E-17 192,659 
EST 49 GNAS-EDN3 rs6026748 20 57,745,815 A/G 0.125 SBP & DBP 0.867 0.089 3.15E-22 192,338   0.552 0.055 4.86E-24 192,327 
34 
Table 2.  Overview of novel and known BP variant properties. 
  
 17 new loci 49 established loci 66 loci 
Minor allele frequency 
(mean, range) 
32.1% [5%-50%] 28.9% [7%-49%] 29.8% [5%-50%] 
Effect size SBP [mmHg] 
(range, mean) 
0.09-0.59, 0.34 0.07-1.13, 0.5 0.07-1.13, 0.46 
Effect size DBP [mmHg] 
(range, mean) 
0.1-0.46, 0.23 0.06-0.60, 0.3 0.06-0.6, 0.28 
Variance explained SBP 0.52% 2.95% 3.46% 
Variance explained DBP 0.58% 2.78% 3.36% 
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Table 3.  BP risk score effects on disease outcomes. 
  
Phenotype Var. 
type 
(cont./
dic.) 
Eth. Consort. Total N 
or no. 
ca/co 
Total 
#SNPs 
SBP_score   DBP_score 
    effect 
(all) 
P value 
(all) 
het.  P 
value (all) 
P value 
(p) 
# 
SNPs  
rem. 
  effect 
(all) 
P value 
(all) 
het. P 
value (all) 
P value 
(p) 
# 
SNPs 
rem. 
HEART              
CAD  dich. EUR
SAS 
CARDIoG
RAMplus
C4D 
63,746 
/130,681 
61 1.042 1.72E-44 1.75E-25 4.08E-32 10   1.069 1.19E-42 6.63E-27 2.2E-38 10 
heart failure dich. EUR CHARGE 2,526 
/18,400  
66 1.021 2.77E-02 1.63E-01 2.77E-02 0  1.035 2.31E-02 1.70E-01 2.31E-02 0 
LV mass cont. EUR CHARGE 11,273 66 0.480 6.43E-04 3.58E-01 6.43E-04 0   0.754 1.23E-03 3.21E-01 1.23E-03 0 
LV wall thickness cont. EUR CHARGE 11,311 66 0.004 4.45E-06 5.83E-02 4.45E-06 0   0.007 3.19E-06 6.40E-02 3.19E-06 0 
KIDNEY                           
CKD  dich. EUR CHARGE 6,271 
/68,083 
65 1.010 1.37E-01 1.77E-03 2.65E-01 1  1.008 4.49E-01 1.25E-03 7.69E-01 1 
eGFR (based on cr)  cont. EUR CHARGE  74,354 65 0.000 7.07E-01 3.12E-05 3.22E-01 2   0.000 9.41E-01 3.02E-05 9.65E-01 2 
eGFR (based on 
cystatin)  
cont. EUR CHARGE 74,354 65 0.001 9.05E-02 9.28E-06 4.11E-01 1   0.001 3.30E-01 5.64E-06 6.9E-01 1 
creatinine  cont. EUR KidneyGE
N 
23,812 66 0.000 9.42E-01 6.31E-03 9.42E-01 0   0.000 4.11E-01 7.16E-03 4.11E-01 0 
microalbuminuria  dich. EUR CHARGE 2,499 
/29,081 
65 0.011 2.10E-01 4.79E-02 2.1E-01 0  0.023 1.02E-01 5.66E-02 1.02E-02 0 
urinary albumin/cr 
ratio 
cont. EUR CHARGE 31,580 65 0.009 2.52E-03 3.02E-04 0.53E-03 1   0.015 2.40E-03 3.08E-04 8.31E-03 1 
STROKE                           
stroke, all subtypes dich. EUR CHARGE 1,544 
/18,058 
66 0.056 6.11E-06 8.26E-02 6.11E-06 0  0.085 3.79E-05 4.98E-02 3.79E-05 0 
stroke, ischemic 
subtype 
dich. EUR CHARGE 1,164 
/18,438 
66 0.067 3.33E-06 1.75E-01 3.33E-06 0   0.096 5.63E-05 8.82E-02 5.63E-05 0 
stroke, ischemic 
subtype 
dich. EUR MetaStro
ke 
11,012 
/40,824 
66 0.036 1.69E-10 4.72E-02 1.69E-10 0  0.056 1.29E-09 2.51E-02 1.29E-09 0 
VASCULATURE                         
cIMT cont. EUR CHARGE 27,610 66 0.004 4.80E-15 5.06E-08 7.32E-10 4   0.005 4.15E-11 3.84E-10 6.2E-07 5 
EYE                           
mild retinop. dich. EUR CHARGE 1,122 
/18,289 
66 1.021 1.37E-01 6.01E-03 1.37E-01 0  1.046 5.78E-02 7.81E-03 5.78E-02 0 
central retinal artery 
caliber 
cont. EUR CHARGE 18,576 66 0.343 3.29E-14 2.56E-06 2.06E-13 2   0.570 3.61E-14 2.44E-06 7.05E-13 3 
mild retinop. dich. EAS SEED 289 
/5,419 
66 1.033 2.55E-01 2.42E-01 2.55E-01 0  1.087 8.55E-02 2.87E-01 8.55E-02 0 
central retinal artery 
caliber 
cont. EAS SEED 6,976 63 0.320 1.39E-04 9.07E-01 1.39E-04 0   0.533 2.19E-04 8.91E-01 2.19E-04 0 
36 
ONLINE METHODS 
Cohorts contributing to systolic (SBP) and diastolic blood pressure (DBP) analyses 
Studies contributing to BP association discovery including community- and population-based 
collections as well as studies of non-BP traits, analyzed as case and control samples separately.  Details 
on each of the studies including study design and BP measurement are provided in Supplementary 
Table 1, genotyping information in Supplementary Table 2, and participant characteristics in 
Supplementary Table 3.  All participants provided written informed consent and the studies were 
approved by local Research Ethics Committees and/or Institutional Review Boards. 
European ancestry meta-analysis 
BP was measured using standardized protocols in all studies regardless of whether the primary 
focus was BP or another trait.  We initially analyzed affected and unaffected individuals from samples 
selected as cases (e.g. type 2 diabetes) or controls, separately.  However, because sensitivity analyses 
did not reveal any significant difference in BP effect size estimates between case and control samples 
(data not shown), we analyzed all samples combined.  When available, the average of two BP 
measurements was used for association analyses (Supplementary Table 1). If an individual was taking a 
BP-lowering treatment, the underlying systolic BP (SBP) and diastolic BP (DBP) were estimated by adding 
15 mmHg and 10 mmHg, respectively, to the measured values, as done in prior analyses. 
A meta-analysis of 340,934 individuals of European descent was undertaken in four stages with 
subsequent validation in an independent cohort. Because stage 1 Cardio-MetaboChip samples included 
many SNPs selected on the basis of association with BP in earlier GWAS, we performed genomic control 
using a set of putative null SNPs based on P > 0.10 in earlier GWAS of SBP and DBP or both.  Stage 2 
samples with genome-wide genotyping used the entire genome-wide set of SNPs for genomic control 
given the lack of ascertainment.  The study design is summarized in Supplementary Figure 1, and further 
details are provided in Supplementary Tables 2-5 and the Supplementary Note. 
Systematic PubMed search +/- 100kb of each newly discovered index SNP 
All genes with any overlap with a 200kb region centered around each of the 17 newly discovered 
lead SNPs were identified using the UCSC Genome Browser.  A search term was constructed for each 
gene including the short and long gene name and the terms “blood pressure” and “hypertension” (e.g. 
for NPPA on chr 1: “NPPA OR natriuretic peptide A AND (blood pressure OR hypertension)”) and the 
search results of each search term from PubMed were individually reviewed. 
Trait variance explained 
The trait variance explained by 66 lead SNPs at novel and known loci was evaluated in one study 
that contributed to the discovery effort: the Atherosclerosis Risk in Communities (ARIC) study.  We 
constructed a linear regression model with all 66 or the subset of 49 known SNPs as a set of predictors 
of the BP residual after adjustment for covariates of the adjusted treatment-corrected BP phenotype 
(SBP or DBP).  The r2 from the regression model was used as the estimate of trait variance explained. 
European ancestry GCTA-COJO analysis 
To identify multiple distinct association signals at any given BP locus, we undertook approximate 
conditional analyses using a model selection procedure implemented in the GCTA-COJO software 
package44,45.  To evaluate the robustness of the GCTA-COJO results to the choice of reference data set, 
model selection was performed using the LD between variants in separate analyses from two datasets of 
European descent, both with individuals from the UK with Cardio-MetaboChip genotype data: GoDARTS 
with 7,006 individuals and WTCCC1-T2D/58BC with 2,947 individuals.  Assuming that the LD between 
37 
SNPs more than 10 Mb away or on different chromosomes is zero, we undertook the GCTA-COJO step-
wise model selection to select SNPs that were conditionally-independently associated with SBP and DBP, 
in turn, at a genome-wide significance, given by P < 5×10-8 (Supplementary Tables 6-8) using the stage 4 
combined European GWAS+ Cardio-MetaboChip meta-analysis. 
Conditional analyses in the Women’s Genome Health Study (WGHS) 
Multivariable regression modeling was performed for each possible combination of putative 
independent SNPs from a) model selection implemented in GCTA-COJO and b) a comprehensive manual 
review of the literature (Supplementary Table 9).  Any SNP with P < 5x10-8 in a previous reported BP 
GWAS was considered.  A total of 46 SNPs were examined (Supplementary Table 10).  Genome-wide 
genotyping data imputed to 1000 Genomes in the WGHS (N = 23,047) were used.  Regression modeling 
was performed in the R statistical language (Supplementary Table 10). 
Fine mapping and determination of credible sets of causal SNPs 
The GCTA-COJO and WGHS conditional analyses identified multiple distinct signals of association at 
multiple loci (Supplementary Tables 6 and 10).  Of the 24 loci considered in fine-mapping analyses, 16 
had no evidence for the existence of multiple distinct association signals, so it is reasonable to assume 
that there is a single causal SNP and therefore the credible sets of variants could be constructed using 
the association summary statistics from the unconditional meta-analyses.  However, in the remaining 
eight loci, where evidence of secondary signals was observed from GCTA-COJO, we performed 
approximate conditional analyses across the region by conditioning on each index SNP (Supplementary 
Table 11).  By adjusting for the other index SNPs at the locus, we can therefore assume a single variant is 
driving each “conditionally-independent” association signal, and we can construct the 99% credible set 
of variants on the basis of the approximate conditional analysis from GCTA-COJO (Supplementary 
Tables 12-13).  At five of the eight loci with multiple distinct signals of association, one index SNP 
mapped outside of the fine-mapping region, so a credible set could not be constructed. 
eQTL analysis: Whole Blood 
NESDA/NTR: Whole blood eQTL analyses were performed in samples from the Netherlands 
Study of Depression and Anxiety (NESDA)46 and the Netherlands Twin Registry (NTR)47 studies. RNA 
expression analysis was performed in the statistical software R.  The residuals resulting from the linear 
regression analysis of the probe set intensity values onto the covariates sex, age, body mass index 
(kg/m2), smoking status coded as a categorical covariate, several technical covariates, and three 
principal components were used. The eQTL effects were detected using a linear mixed model approach, 
including for each probe set the expression level (normalized, residualized and without the first 50 
expression PCs) as dependent variable; the SNP genotype values as fixed effects; and family identifier 
and zygosity (in the case of twins) as random effects to account for family and twin relations48. 
The eQTL effects were defined as cis when probe set–SNP pairs were at distance < 1M base 
pairs.  At a FDR of 0.01 applied genome-wide, not just for candidate SNPs, the P value threshold was 
1x10-4 for the cis-eQTL analysis.  For each probe set that displayed a statistically significant association 
with at least one SNP located within its cis region, we identified the most significantly associated SNP 
and denoted this as the top cis-eQTL SNP. See Supplementary Note for details. 
eQTL analysis: Selected published eQTL datasets 
Lead BP SNP and proxies (r2 > 0.8) were searched against a collected database of expression SNP 
(eSNP) results.  The reported eSNP results met criteria for statistical thresholds for association with gene 
transcript levels as described in the original papers.  The non-blood cell tissue eQTLs searched included 
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aortic endothelial cells49, left ventricle of the heart 50, cd14+ monocytes 51 and the brain 52. The results 
are presented in Supplementary Tables 14-15. 
Enrichment analyses: Analysis of cell-specific DNase hypersensitivity sites (DHSs) using an OR method 
The overlap of Cardio-MetaboChip SNPs with DHSs was examined using publicly available data 
from the Epigenomics Roadmap Project and ENCODE, choosing different cutoffs of Cardio-MetaboChip P 
values.  The DHS mappings were available for 123 mostly adult cells and tissues 53 (downloaded from 
The DHS mappings were specified as both “narrow” and “broad” peaks, referring to reduction of the 
experimental data to peak calls at 0.1% and 1.0% FDR thresholds, respectively.  Thus, the “narrow” 
peaks are largely nested within the “broad” peaks. Experimental replicates of the DHS mappings 
(typically duplicates) were also available for the majority of cells and tissues. 
 SNPs from the Cardio-MetaboChip genome-wide scan were first clumped in PLINK in windows of 
100kb and maximum r2 = 0.1 among LD relationships from the 1000 Genomes European data.  Then, the 
resulting index SNPs at each P value threshold were tagged with r2 = 0.8 in windows of 100kb, again 
using LD relationships in the 1000 Genomes, restricted to SNPs with MAF > 1% and also present in the 
HapMap2 CEU population.  A reference set of SNPs was constructed using the same clumping and 
tagging procedures applied to GWAS catalog SNPs (available at http://www.genome.gov/gwastudies/, 
accessed 3/13/2013)54 with discovery P < 5x10-8 in European populations.  A small number of reference 
SNPs or their proxies overlapping the BP SNPs or their proxies were excluded.  After LD pruning and 
exclusions, there were a total of 1,196 reference SNPs. For each cell type and P value threshold, the 
enrichment of SBP or DBP SNPs (or their LD proxies) mapping to DHSs was expressed as an odds ratio 
(OR) relative to the GWAS catalog reference SNPs (or their LD proxies), using logistic mixed effect 
models treating the replicate peak determinations as random effects (glmer package in R).  The 
significance of the enrichment ORs was derived from the significance of beta coefficients for the main 
effects in the mixed models (Figure 2, Supplementary Table 16). 
Enrichment analyses: Analysis of tissue-specific enrichment of BP variants and H3K4me3 sites 
An analysis to test for significant cell-specific enrichment in the overlap of BP SNPs (or their 
proxies) with H3K4me3 sites was performed as described in Trynka et al, 201355.  The measure of 
overlap is a “score” that is constructed by dividing the height of an H3K4me3 ChIP signal in a particular 
cell by the distance between the nearest test SNP.  The significance of the scores (i.e. P value) for all 
SNPs was determined by a permutation approach that compares the observed scores to scores of SNPs 
with similar properties to the test SNPs, essentially in terms of LD and proximity to genes 
(Supplementary Note).  The number of permutations determined the number of significant digits in the 
P values and we conducted 10,000 iterations. Results are shown in Supplementary Table 19. 
Enrichment analyses: Analysis of tissue-specific DHSs and chromatin states using GREGOR 
The DNase-seq ENCODE data for all available cell types were downloaded in the processed 
“narrowPeak” format. The local maxima of the tag density in broad, variable-sized “hotspot” regions of 
chromatin accessibility were thresholded at FDR 1% with peaks set to a fixed width of 150bp.  Individual 
cell types were further grouped into 41 broad tissue categories by taking the union of DHSs for all 
related cell types and replicates. For each GWAS locus, a set of matched control SNPs was selected 
based on three criteria: 1) number of variants in LD (r2 > 0.7; ± 8 variants), 2) MAF (± 1%), and 3) distance 
to nearest gene (± 11,655 bp). To calculate the distance to the nearest gene, the distance to the 5’ 
flanking gene (start and end position) and to the 3’ flanking gene was calculated and the minimum of 
these 4 values was used. If the SNP fell within the transcribed region of a gene, the distance was 0.  The 
probability that a set of GWAS loci overlap with a regulatory feature more often than we expect by 
chance was estimated. 
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Enrichment analyses: FAIRE analysis of BP variants in fine-mapping regions in lymphoblastoid cell lines 
FAIRE analysis was performed on a sample of 20 lymphoblastoid cell lines of European origin. All 
samples were genotyped using the Cardio-MetaboChip genotyping array, and BP SNPs and LD proxies (r2 
> 0.8) at the fine mapping loci (N = 24, see Supplementary Table 23) were assessed to identify 
heterozygous imbalance between non-treated and FAIRE-treated chromatin. A paired t-test was used to 
compare the B allele frequency (BAF) arising from formaldehyde-fixed chromatin sheared by sonication 
and DNA purified to the BAF when the same chromatin sample underwent FAIRE to enrich for open 
chromatin. Three hundred and fifty-seven Cardio-MetaboChip BP SNPs were directly genotyped across 
the fine mapping regions. The Bonferroni-corrected threshold of significance is P < 0.0001 (0.05/357).  
The results for SNPs with P < 0.05 are reported in (Supplementary Table 23). FAIRE results were not 
available for some SNPs with missing data due to genotype failure or not having >3 heterozygous 
individuals for statistical analysis. Therefore there are no results for three lower frequency BP loci 
(SLC39A8, CYP17A1-NT5C2 and GNAS-EDN3) and for the second signal at the following loci: MTHFR-
NPPB (rs2272803), MECOM (rs2242338) and HFE rs1800562). 
Pathway analyses: MAGENTA 
MAGENTA tests for enrichment of gene sets from a precompiled library derived from GO, KEGG, 
PATHTER, REACTOME, INGENUITY, and BIOCARTA was performed as described by Segré et al, 201056.  
Enrichment of significant gene-wide P values in gene sets is assessed by 1) using LD and distance criteria 
to define the span of each gene, 2) selecting the smallest P value among SNPs mapping to the gene 
span, and 3) adjusting this P value using a regression method that accounts for the number of SNPs, the 
LD, etc.  In the second step, MAGENTA examines the distribution of these adjusted P values and defines 
thresholds for the 75%ile and the 95%ile.  In the third step, MAGENTA calculates an enrichment for each 
gene set by comparing the number of genes in the gene set with P value less than either the 75th or 
95th %ile to the number of genes in the gene set with P value greater than either the 75th or 95th %ile, 
and then comparing this quotient to the same quotient among genes not in the gene set.  This gene-set 
quotient is assigned a P value based on reference to a hypergeometric distribution.  The results based 
on our analyses are indicated in Supplementary Table 21. 
Pathway analyses: DEPICT 
We applied the DEPICT 57 analysis separately on genome-wide significant loci from the overall blood 
pressure (BP) Cardio-MetaboChip analysis including published blood pressure loci (see Supplementary 
Table 22). SNPs at the HFE and BAT2-BAT5 loci (rs1799945, rs1800562, rs2187668, rs805303, 
rs9268977) could not be mapped.  As a secondary analysis, we additionally included associated loci (P < 
1x10-5) from the Cardio-MetaboChip stage 4 combined meta-analyses of SBP and the DBP.  DEPICT 
assigned genes to associated regions if they overlapped or resided within associated LD blocks with r2 > 
0.5 to a given associated SNP. 
Literature review for genes at the newly discovered loci 
Recognizing that the most significantly associated SNP at a locus may not be located in the causal 
gene and that the functional consequences of a SNP often extends beyond 100kb, we conducted a 
literature review of genes in extended regions around newly discovered BP index SNPs.  The genes for 
this extensive review were identified by DEPICT (Supplementary Table 22). 
Non-European meta-analysis 
To assess the association of the 66 significant loci from the European ancestry meta-analysis in non-
European ethnicities, we obtained lookup results for the 66 index SNPs for participants of South-Asian 
ancestry (8 datasets, total N = 20,875), East-Asian ancestry (5 datasets, total N = 9,637), and African- and 
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African-American ancestry (6 datasets, total N = 33,909).  The association analyses were all conducted 
with the same covariates (age, age2, sex, BMI) and treatment correction (+15/10 mm Hg in the presence 
of any hypertensive medication) as the association analyses for the discovery effort in Europeans. Tests 
for heterogeneity across effect estimates in European, South Asian, East Asian and African derived 
samples were performed using GWAMA58. 
Genetic risk score and cardiovascular outcomes 
The gtx package for the R statistical programming language was used to estimate the effect of the 
SNP-risk score on the response variable in a regression model59. 
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